论文部分内容阅读
长期以来,对乳腺癌进行辅助性全身治疗的评价一直存有争议,近15年,不少学者对此做了深入研究,以求可行手术治疗的早期乳腺癌在局部切除术后,通过辅助性全身治疗达到根治残留的微小转移灶,延缓癌瘤复发,从而延长病人的生命。作者认为,自1983年第三届国际乳腺癌讨论会以来,乳腺癌的辅助治疗有了很大进展,当时认为辅助性化疗在一些亚群中可降低复发和提高生存率,同时对想从未经验证的辅助化疗的新方法寻求支持,又不设立非治疗对照组
For a long time, the assessment of adjuvant systemic therapy for breast cancer has been controversial. In the past 15 years, many scholars have conducted an in-depth study to seek feasible surgical treatment of early breast cancer after partial resection, through auxiliary Systemic treatment reaches the micrometastases of radical remnants and delays the recurrence of cancerous tumors, thereby prolonging the patient’s life. The author believes that since the 3rd International Breast Cancer Symposium in 1983, the adjuvant treatment of breast cancer has made great progress. At that time, adjuvant chemotherapy was considered to reduce recurrence and improve survival in some subgroups. New methods of validated adjuvant chemotherapy seek support without establishing non-treatment control groups